DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Upgraded by Oppenheimer

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]

Related Keywords

Davidj Wambeke , ,Renaissance Technologies ,Diamedica Therapeutics Inc ,Diamedica Therapeutics Company Profile ,Dimensional Fund Advisors ,Securities Exchange Commission ,Catalyst Financial Partners ,Citadel Advisors ,Diamedica Therapeutics ,Get Rating ,Medica Therapeutics ,Exchange Commission ,Financial Partners ,Street Corp ,Fund Advisors ,Medica Therapeutics Inc ,Diamedica Therapeutics Daily ,Nasdaq Dmac ,Sdmac ,Medical ,Upgrade ,Oppenheimer Holdings Inc ,